Skip to content

13F-HR filed by Fairmount Funds Management LLC

Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 12 holding rows worth $1,512,967,797.

Accession
0001104659-26-096405
Filed
2026-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2026

A holdings report, 12 entries on the cover page, a total value of $1,512,967,797 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,512,967,797 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ORUKA THERAPEUTICS INC COM687604108Stock3,705,262$352,629,785dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM2,537,191$247,325,379dollars as filed
DAMORA THERAPEUTICS INC36322Q206COMMON STOCK8,713,000$226,625,130dollars as filed
COGENT BIOSCIENCES INC19240Q201COM5,503,418$212,982,277dollars as filed
JADE BIOSCIENCES INC008064206COM NEW4,553,494$101,178,637dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock1,855,644$94,173,933dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM5,090,928$93,520,347dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock2,359,025$59,872,055dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK2,747,866$49,461,588dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock298,647$39,639,416dollars as filed
FAETH THERAPEUTICS INC81728A207COM NEW722,020$18,050,500dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK8,625,000$17,508,750dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-26-096405this filing2026-08-14acceptance time not in the bulk data set